Analysts’ Viewpoint on Market Scenario
Mice are small and relatively easy to handle and transport. They can also be reproduced quickly. This is expected to result in the global mice model generation industry growth during the forecast period.
Rise in usage of genetically engineered mouse model (GEMM) for drug discovery purposes is expected to drive the mice model generation market demand from 2022 to 2031.
Rapid technological advancements have been taking place in mouse model generation, resulting in transgenic mice generation, knock-in mouse generation, and knock-out mouse generation. Need for effective COVID-19 vaccines to control the pandemic and eradicate the virus is augmenting the global market.
Governments of various countries are taking initiatives to discover effective vaccines and medications for several types of chronic diseases. This is likely to provide lucrative opportunities to players operating in the global market.
Mice are efficient and cost-effective research tools. Mice model inception began in the early 1900s on a farm in Granby, Massachusetts. Mice models are more advantageous than other animal models, as 99% of their genome is similar to the human genome.
Rise in prevalence of cancer, cardiovascular diseases, diabetes, autism, schizophrenia, and rare diseases; increase in the burden of obesity; and growth of genetic disorders are propelling the global mice model generation market. Emergence of CRISPR as a powerful tool in the field of biomedical research and surge in applications of CRISPR technology in several industry segments are augmenting the global mice model market.
Advancement in gene technology, fueled by the need for fast and accurate treatment, in the ever-evolving medical industry is driving the mice model market. Identification of genomic differences to predict drug resistance or drug response by the patients could offer scope to design a customized therapy according to specific characteristics of a particular cancer.
Study of cancer in mouse models has gained popularity over the last few decades. Sophisticated genetic manipulation technologies and commercialization of these murine systems have made it possible to generate mice models to study human disease.
Given the large socio-economic burden of cancer, both on academic research and the healthcare industry, there is a need for in vivo animal cancer models that can provide a rationale that is translatable to the clinic. Such a bench-to-bedside transition is likely to facilitate long-term growth of the global mice model generation market. The Mouse Avatar and Co-clinical Trial concepts have the potential to revolutionize the drug development and healthcare process.
In terms of technology, the global market has been segmented into CRISPR knockout, CRISPR knockin, random insertions, large & targeted insertions, ES cell modification (homologous recombination), and others. The CRISPR knockout segment held dominant share of the market in 2021. The segment is likely to lead the global market during the forecast period by registering the highest CAGR.
High efficiency and flexibility of the CRISPR gene editing technology is expected to drive the CRISPR knockout segment during the forecast period. As per the global mice model generation market trends, usage of CRISPR technology for the development of CRISPR knockout mice is likely to increase in the next few years.
Based on end-user, the global market has been classified into pharmaceutical companies, biotechnology companies, academic & research facilities, and contract research & manufacturing organizations.
The biotechnology companies segment is projected to account for significant share of the global mice model generation market from 2022 to 2031. The segment is anticipated to exhibit the highest CAGR during the forecast period.
High adoption of CRISPR technology by biotechnology companies and research laboratories is driving the segment. For instance, in October 2016, Caribou Biosciences granted The Jackson Laboratory non-exclusive worldwide rights to use its CRISPR-Cas9 intellectual property to create genetically engineered mice for research purposes.
However, the academic & research facilities segment is expected to register the highest growth rate during the forecast period. Increase in funding for academic research institutes for mice model research is augmenting the segment.
North America dominated the global market, with more than 40% share in 2021. Well-established pharmaceutical & biopharmaceutical research industry and presence of some of the world’s leading pharmaceutical and biopharmaceutical companies in the region make it highly promising for various products employed in research activities. This is projected to drive the mice model generation market in North America during the forecast period.
The market in Asia Pacific is expected to grow at the fastest CAGR during the forecast period. Increase in the usage of mice models for research purposes due to the COVID-19 outbreak is anticipated to drive the market in the region during the forecast period.
The global mice model generation market is consolidated, with the presence of international as well as local players. Top five or six players account for the major share of the market. Manufacturers strive to build a strong network of vendors to enable seamless distribution of products among the consumers.
Leading vendors in the global market are striving to increase their presence across the globe and build a distribution network through collaborations and partnerships. Mergers, acquisitions, joint ventures, collaborations, and partnerships are important expansion strategies adopted by key players in the mice model generation industry.
Prominent players operating in the global market are Biocytogen, Charles River Laboratories, Cyagen Biosciences, Gempharmatech, genOway, Ingenious Targeting Laboratory, Ozgene Pty Ltd., Taconic Biosciences, Inc., PolyGene AG, The Jackson Laboratory, Yale School of Medicine, University of North Carolina, University of Nebraska Medical Center, Monash University, UMass Chan Medical School, University of Bonn, Columbia University, The University of Arizona, The Weizmann Institute of Science, The Hebrew University of Jerusalem, The Technion – Israel Institute of Technology, and Hadassah BrainLabs.
Each of these players has been profiled in the mice model generation market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 424.6 Mn |
|
Market Forecast Value in 2031 |
More than US$ 918.4 Mn |
|
Growth Rate (CAGR) |
8.1% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
It was valued at US$ 424.6 Mn in 2021
It is projected to reach more than US$ 918.4 Mn by 2031
The global market grew at a CAGR of 7.4% from 2017 to 2021
It is anticipated to grow at a CAGR of 8.1% from 2022 to 2031
Rise in prevalence of cancer, cardiovascular diseases, diabetes, autism, schizophrenia, and rare diseases; increase in burden of obesity; emergence of CRISPR as a powerful tool in the field of biomedical research; surge in application of CRISPR technology in various industry segments; and growth in incidence of genetic disorders
The CRISPR knockout segment accounted for more than 35% share of the global mice model generation market in 2021
North America is expected to account for major share of the global market during the forecast period.
Biocytogen, Charles River Laboratories, Cyagen Biosciences, Gempharmatech, genOway, Ingenious Targeting Laboratory, Ozgene Pty Ltd., Taconic Biosciences, Inc., PolyGene AG, The Jackson Laboratory, Yale School of Medicine, University of North Carolina, University of Nebraska Medical Center, Monash University, UMass Chan Medical School, University of Bonn, Columbia University, The University of Arizona, The Weizmann Institute of Science, The Hebrew University of Jerusalem, The Technion – Israel In
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Mice Model Generation Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Mice Model Generation Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Global Genetically Engineered Mouse Model Overview
5.2. Regulatory Scenario by Region/globally
5.3. Technological Advancements
5.4. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
5.5. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Mice Model Generation Market Analysis and Forecast, by Technology
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Technology, 2017–2031
6.3.1. CRISPR Knockout
6.3.2. CRISPR Knockin
6.3.3. Random Insertions
6.3.4. Large, Targeted Insertions
6.3.5. ES Cell Modification (homologous recombination)
6.3.6. Others
6.4. Market Attractiveness Analysis, by Technology
7. Global Mice Model Generation Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2017–2031
7.3.1. Pharmaceutical Companies
7.3.2. Biotechnology Companies
7.3.3. Academic & Research Facilities
7.3.4. Contract Research & Manufacturing Organizations
7.4. Market Attractiveness Analysis, by End-user
8. Global Mice Model Generation Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Mice Model Generation Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Technology, 2017–2031
9.2.1. CRISPR Knockout
9.2.2. CRISPR Knockin
9.2.3. Random Insertions
9.2.4. Large, Targeted Insertions
9.2.5. ES Cell Modification (homologous recombination)
9.2.6. Others
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Pharmaceutical Companies
9.3.2. Biotechnology Companies
9.3.3. Academic & Research Facilities
9.3.4. Contract Research & Manufacturing Organizations
9.4. Market Value Forecast, by End-user by Technology, 2017–2031
9.4.1. Pharmaceutical Companies
9.4.1.1. CRISPR Knockout
9.4.1.2. CRISPR Knockin
9.4.1.3. Random Insertions
9.4.1.4. Large, Targeted Insertions
9.4.1.5. ES Cell Modification (homologous recombination)
9.4.1.6. Others
9.4.2. Biotechnology Companies
9.4.2.1. CRISPR Knockout
9.4.2.2. CRISPR Knockin
9.4.2.3. Random Insertions
9.4.2.4. Large, Targeted Insertions
9.4.2.5. ES Cell Modification (homologous recombination)
9.4.2.6. Others
9.4.3. Academic & Research Facilities
9.4.3.1. CRISPR Knockout
9.4.3.2. CRISPR Knockin
9.4.3.3. Random Insertions
9.4.3.4. Large, Targeted Insertions
9.4.3.5. ES Cell Modification (homologous recombination)
9.4.3.6. Others
9.4.4. Contract Research & Manufacturing Organizations
9.4.4.1. CRISPR Knockout
9.4.4.2. CRISPR Knockin
9.4.4.3. Random Insertions
9.4.4.4. Large, Targeted Insertions
9.4.4.5. ES Cell Modification (homologous recombination)
9.4.4.6. Others
9.5. Market Value Forecast, by Country, 2017–2031
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Technology
9.6.2. By End-user
9.6.3. By End-user by Technology
9.6.4. By Country
10. Europe Mice Model Generation Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Technology, 2017–2031
10.2.1. CRISPR Knockout
10.2.2. CRISPR Knockin
10.2.3. Random Insertions
10.2.4. Large, Targeted Insertions
10.2.5. ES Cell Modification (homologous recombination)
10.2.6. Others
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Pharmaceutical Companies
10.3.2. Biotechnology Companies
10.3.3. Academic & Research Facilities
10.3.4. Contract Research & Manufacturing Organizations
10.4. Market Value Forecast, by End-user by Technology, 2017–2031
10.4.1. Pharmaceutical Companies
10.4.1.1. CRISPR Knockout
10.4.1.2. CRISPR Knockin
10.4.1.3. Random Insertions
10.4.1.4. Large, Targeted Insertions
10.4.1.5. ES Cell Modification (homologous recombination)
10.4.1.6. Others
10.4.2. Biotechnology Companies
10.4.2.1. CRISPR Knockout
10.4.2.2. CRISPR Knockin
10.4.2.3. Random Insertions
10.4.2.4. Large, Targeted Insertions
10.4.2.5. ES Cell Modification (homologous recombination)
10.4.2.6. Others
10.4.3. Academic & Research Facilities
10.4.3.1. CRISPR Knockout
10.4.3.2. CRISPR Knockin
10.4.3.3. Random Insertions
10.4.3.4. Large, Targeted Insertions
10.4.3.5. ES Cell Modification (homologous recombination)
10.4.3.6. Others
10.4.4. Contract Research & Manufacturing Organizations
10.4.4.1. CRISPR Knockout
10.4.4.2. CRISPR Knockin
10.4.4.3. Random Insertions
10.4.4.4. Large, Targeted Insertions
10.4.4.5. ES Cell Modification (homologous recombination)
10.4.4.6. Others
10.5. Market Value Forecast, by Country/Sub-region, 2017–2031
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Technology
10.6.2. By End-user
10.6.3. By End-user by Technology
10.6.4. By Country/Sub-region
11. Asia Pacific Mice Model Generation Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Technology, 2017–2031
11.2.1. CRISPR Knockout
11.2.2. CRISPR Knockin
11.2.3. Random Insertions
11.2.4. Large, Targeted Insertions
11.2.5. ES Cell Modification (homologous recombination)
11.2.6. Others
11.3. Market Value Forecast, by End-user, 2017–2031
11.3.1. Pharmaceutical Companies
11.3.2. Biotechnology Companies
11.3.3. Academic & Research Facilities
11.3.4. Contract Research & Manufacturing Organizations
11.4. Market Value Forecast, by End-user by Technology, 2017–2031
11.4.1. Pharmaceutical Companies
11.4.1.1. CRISPR Knockout
11.4.1.2. CRISPR Knockin
11.4.1.3. Random Insertions
11.4.1.4. Large, Targeted Insertions
11.4.1.5. ES Cell Modification (homologous recombination)
11.4.1.6. Others
11.4.2. Biotechnology Companies
11.4.2.1. CRISPR Knockout
11.4.2.2. CRISPR Knockin
11.4.2.3. Random Insertions
11.4.2.4. Large, Targeted Insertions
11.4.2.5. ES Cell Modification (homologous recombination)
11.4.2.6. Others
11.4.3. Academic & Research Facilities
11.4.3.1. CRISPR Knockout
11.4.3.2. CRISPR Knockin
11.4.3.3. Random Insertions
11.4.3.4. Large, Targeted Insertions
11.4.3.5. ES Cell Modification (homologous recombination)
11.4.3.6. Others
11.4.4. Contract Research & Manufacturing Organizations
11.4.4.1. CRISPR Knockout
11.4.4.2. CRISPR Knockin
11.4.4.3. Random Insertions
11.4.4.4. Large, Targeted Insertions
11.4.4.5. ES Cell Modification (homologous recombination)
11.4.4.6. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Technology
11.6.2. By End-user
11.6.3. By End-user by Technology
11.6.4. By Country/Sub-region
12. Latin America Mice Model Generation Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Technology, 2017–2031
12.2.1. CRISPR Knockout
12.2.2. CRISPR Knockin
12.2.3. Random Insertions
12.2.4. Large, Targeted Insertions
12.2.5. ES Cell Modification (homologous recombination)
12.2.6. Others
12.3. Market Value Forecast, by End-user, 2017–2031
12.3.1. Pharmaceutical Companies
12.3.2. Biotechnology Companies
12.3.3. Academic & Research Facilities
12.3.4. Contract Research & Manufacturing Organizations
12.4. Market Value Forecast, by End-user by Technology, 2017–2031
12.4.1. Pharmaceutical Companies
12.4.1.1. CRISPR Knockout
12.4.1.2. CRISPR Knockin
12.4.1.3. Random Insertions
12.4.1.4. Large, Targeted Insertions
12.4.1.5. ES Cell Modification (homologous recombination)
12.4.1.6. Others
12.4.2. Biotechnology Companies
12.4.2.1. CRISPR Knockout
12.4.2.2. CRISPR Knockin
12.4.2.3. Random Insertions
12.4.2.4. Large, Targeted Insertions
12.4.2.5. ES Cell Modification (homologous recombination)
12.4.2.6. Others
12.4.3. Academic & Research Facilities
12.4.3.1. CRISPR Knockout
12.4.3.2. CRISPR Knockin
12.4.3.3. Random Insertions
12.4.3.4. Large, Targeted Insertions
12.4.3.5. ES Cell Modification (homologous recombination)
12.4.3.6. Others
12.4.4. Contract Research & Manufacturing Organizations
12.4.4.1. CRISPR Knockout
12.4.4.2. CRISPR Knockin
12.4.4.3. Random Insertions
12.4.4.4. Large, Targeted Insertions
12.4.4.5. ES Cell Modification (homologous recombination)
12.4.4.6. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Technology
12.6.2. By End-user
12.6.3. By End-user by Technology
12.6.4. By Country/Sub-region
13. Middle East & Africa Mice Model Generation Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Technology, 2017–2031
13.2.1. CRISPR Knockout
13.2.2. CRISPR Knockin
13.2.3. Random Insertions
13.2.4. Large, Targeted Insertions
13.2.5. ES Cell Modification (homologous recombination)
13.2.6. Others
13.3. Market Value Forecast, by End-user, 2017–2031
13.3.1. Pharmaceutical Companies
13.3.2. Biotechnology Companies
13.3.3. Academic & Research Facilities
13.3.4. Contract Research & Manufacturing Organizations
13.4. Market Value Forecast, by End-user by Technology, 2017–2031
13.4.1. Pharmaceutical Companies
13.4.1.1. CRISPR Knockout
13.4.1.2. CRISPR Knockin
13.4.1.3. Random Insertions
13.4.1.4. Large, Targeted Insertions
13.4.1.5. ES Cell Modification (homologous recombination)
13.4.1.6. Others
13.4.2. Biotechnology Companies
13.4.2.1. CRISPR Knockout
13.4.2.2. CRISPR Knockin
13.4.2.3. Random Insertions
13.4.2.4. Large, Targeted Insertions
13.4.2.5. ES Cell Modification (homologous recombination)
13.4.2.6. Others
13.4.3. Academic & Research Facilities
13.4.3.1. CRISPR Knockout
13.4.3.2. CRISPR Knockin
13.4.3.3. Random Insertions
13.4.3.4. Large, Targeted Insertions
13.4.3.5. ES Cell Modification (homologous recombination)
13.4.3.6. Others
13.4.4. Contract Research & Manufacturing Organizations
13.4.4.1. CRISPR Knockout
13.4.4.2. CRISPR Knockin
13.4.4.3. Random Insertions
13.4.4.4. Large, Targeted Insertions
13.4.4.5. ES Cell Modification (homologous recombination)
13.4.4.6. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Technology
13.6.2. By End-user
13.6.3. By End-user by Technology
13.6.4. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.2.1. Global
14.2.2. North America
14.2.3. Europe
14.2.4. By Asia Pacific
14.2.5. By Latin America
14.2.6. By Middle East & Africa
14.3. Company Profiles
14.3.1. Biocytogen
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Strategic Overview
14.3.2. Charles River Laboratories
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Strategic Overview
14.3.3. Cyagen Biosciences
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Strategic Overview
14.3.4. Gempharmatech
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Strategic Overview
14.3.5. genOway
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Strategic Overview
14.3.6. ingenious targeting laboratory
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Strategic Overview
14.3.7. Merck KGaA
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Strategic Overview
14.3.8. Ozgene Pty Ltd.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Strategic Overview
14.3.9. Taconic Biosciences, Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Strategic Overview
14.3.10. PolyGene AG
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Strategic Overview
14.3.11. The Jackson Laboratory
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Product Portfolio
14.3.11.3. SWOT Analysis
14.3.11.4. Strategic Overview
14.3.12. Yale School of Medicine
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Product Portfolio
14.3.12.3. SWOT Analysis
14.3.12.4. Strategic Overview
14.3.13. University of North Carolina
14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.13.2. Product Portfolio
14.3.13.3. SWOT Analysis
14.3.13.4. Strategic Overview
14.3.14. University of Nebraska Medical Center
14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.14.2. Product Portfolio
14.3.14.3. SWOT Analysis
14.3.14.4. Strategic Overview
14.3.15. Monash University
14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.15.2. Product Portfolio
14.3.15.3. SWOT Analysis
14.3.15.4. Strategic Overview
14.3.16. UMass Chan Medical School
14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.16.2. Product Portfolio
14.3.16.3. SWOT Analysis
14.3.16.4. Strategic Overview
14.3.17. University of Bonn
14.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.17.2. Product Portfolio
14.3.17.3. SWOT Analysis
14.3.17.4. Strategic Overview
14.3.18. Columbia University
14.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.18.2. Product Portfolio
14.3.18.3. SWOT Analysis
14.3.18.4. Strategic Overview
14.3.19. The University of Arizona
14.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.19.2. Product Portfolio
14.3.19.3. SWOT Analysis
14.3.19.4. Strategic Overview
14.3.20. Hadassah BrainLabs
14.3.20.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.20.2. Product Portfolio
14.3.20.3. SWOT Analysis
14.3.20.4. Strategic Overview
14.3.21. The Weizmann Institute of Science
14.3.21.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.21.2. Product Portfolio
14.3.21.3. SWOT Analysis
14.3.21.4. Strategic Overview
14.3.22. The Hebrew University of Jerusalem
14.3.22.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.22.2. Product Portfolio
14.3.22.3. SWOT Analysis
14.3.22.4. Strategic Overview
14.3.23. The Technion – Israel Institute of Technology
14.3.23.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.23.2. Product Portfolio
14.3.23.3. SWOT Analysis
14.3.23.4. Strategic Overview
List of Tables
Table 01: Price/Cost Analysis of Mice Models, by Region
Table 02: Global Mice Model Generation Market Value (US$ Mn) Forecast, by Technology, 2017‒2031
Table 03: Global Mice Model Generation Market Value (US$ Mn) Forecast, by End-user, 2017‒2031
Table 04: Global Mice Model Generation Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017‒2031
Table 05: Global Mice Model Generation Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017‒2031
Table 06: Global Mice Model Generation Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017‒2031
Table 07: Global Mice Model Generation Market Value (US$ Mn) Forecast, Contract Research & Manufacturing Organizations by Technology, 2017‒2031
Table 08: Global Mice Model Generation Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 09: North America Mice Model Generation Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 10: North America Mice Model Generation Market Value (US$ Mn) Forecast, by Technology, 2017‒2031
Table 11: North America Mice Model Generation Market Value (US$ Mn) Forecast, by End-user, 2017‒2031
Table 12: North America Mice Model Generation Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017‒2031
Table 13: North America Mice Model Generation Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017‒2031
Table 14: North America Mice Model Generation Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017‒2031
Table 15: North America Mice Model Generation Market Value (US$ Mn) Forecast, Contract Research & Manufacturing Organizations by Technology, 2017‒2031
Table 16: Europe Mice Model Generation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Europe Mice Model Generation Market Value (US$ Mn) Forecast, by Technology, 2017‒2031
Table 18: Europe Mice Model Generation Market Value (US$ Mn) Forecast, by End-user, 2017‒2031
Table 19: Europe Mice Model Generation Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017‒2031
Table 20: Europe Mice Model Generation Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017‒2031
Table 21: Europe Mice Model Generation Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017‒2031
Table 22: Europe Mice Model Generation Market Value (US$ Mn) Forecast, Contract Research & Manufacturing Organizations by Technology, 2017‒2031
Table 23: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 24: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, by Technology, 2017‒2031
Table 25: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, by End-user, 2017‒2031
Table 26: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017‒2031
Table 27: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017‒2031
Table 28: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017‒2031
Table 29: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, Contract Research & Manufacturing Organizations by Technology, 2017‒2031
Table 30: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 31: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, by Technology, 2017‒2031
Table 32: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, by End-user, 2017‒2031
Table 33: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017‒2031
Table 34: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017‒2031
Table 35: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017‒2031
Table 36: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, Contract Research & Manufacturing Organizations by Technology, 2017‒2031
Table 37: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 38: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, by Technology, 2017‒2031
Table 39: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, by End-user, 2017‒2031
Table 40: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017‒2031
Table 41: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017‒2031
Table 42: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017‒2031
Table 43: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, Contract Research & Manufacturing Organizations by Technology, 2017‒2031
List of Figures
Figure 01: Global Mice Model Generation Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Mice Model Generation Market Value Share, by Technology, 2021
Figure 03: Global Mice Model Generation Market Value Share, by End-user, 2021
Figure 04: Global Mice Model Generation Market Value Share, by Region, 2021
Figure 05: Global Mice Model Generation Market Value Share Analysis, by Technology, 2021 and 2031
Figure 06: Global Mice Model Generation Market Attractiveness Analysis, by Technology, 2022–2031
Figure 07: Global Mice Model Generation Market Value (US$ Mn), by CRISPR Knockout, 2017‒2031
Figure 08: Global Mice Model Generation Market Value (US$ Mn), by CRISPR Knockin Mice, 2017‒2031
Figure 09: Global Mice Model Generation Market Value (US$ Mn), by Random Insertions, 2017‒2031
Figure 10: Global Mice Model Generation Market Value (US$ Mn), by Large, Targeted Insertions, 2017‒2031
Figure 11: Global Mice Model Generation Market Value (US$ Mn), by ES Cell Modification (homologous recombination), 2017‒2031
Figure 12: Global Mice Model Generation Market Value (US$ Mn), by Others, 2017‒2031
Figure 13: Global Mice Model Generation Market Value Share Analysis, by End-user, 2021 and 2031
Figure 14: Global Mice Model Generation Market Attractiveness Analysis, by End-user, 2022–2031
Figure 15: Global Mice Model Generation Market Value (US$ Mn), by Pharmaceutical Companies, 2017‒2031
Figure 16: Global Mice Model Generation Market Value (US$ Mn), by Biotechnology Companies, 2017‒2031
Figure 17: Global Mice Model Generation Market Value (US$ Mn), by Academic & Research Facilities, 2017‒2031
Figure 18: Global Mice Model Generation Market Value (US$ Mn), by Contract Research & Manufacturing Organizations, 2017‒2031
Figure 19: Global Mice Model Generation Market Value Share Analysis, by Region, 2021 and 2031
Figure 20: Global Mice Model Generation Market Attractiveness Analysis, by Region, 2022–2031
Figure 21: North America Mice Model Generation Market Value (US$ Mn) Forecast, 2017–2031
Figure 23: North America Mice Model Generation Market Attractiveness Analysis, by Country, 2022–2031
Figure 22: North America Mice Model Generation Market Value Share Analysis, by Country, 2021 and 2031
Figure 24: North America Mice Model Generation Market Value Share Analysis, by Technology, 2021 and 2031
Figure 25: North America Mice Model Generation Market Attractiveness Analysis, by Technology, 2022–2031
Figure 26: North America Mice Model Generation Market Value Share Analysis, by End-user, 2021 and 2031
Figure 27: North America Mice Model Generation Market Attractiveness Analysis, by End-user, 2022–2031
Figure 28: Europe Mice Model Generation Market Value (US$ Mn) Forecast, 2017–2031
Figure 30: Europe Mice Model Generation Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 29: Europe Mice Model Generation Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 31: Europe Mice Model Generation Market Value Share Analysis, by Technology, 2021 and 2031
Figure 32: Europe Mice Model Generation Market Attractiveness Analysis, by Technology, 2022–2031
Figure 33: Europe Mice Model Generation Market Value Share Analysis, by End-user, 2021 and 2031
Figure 34: Europe Mice Model Generation Market Attractiveness Analysis, by End-user, 2022–2031
Figure 35: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, 2017–2031
Figure 37: Asia Pacific Mice Model Generation Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 36: Asia Pacific Mice Model Generation Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 38: Asia Pacific Mice Model Generation Market Value Share Analysis, by Technology, 2021 and 2031
Figure 39: Asia Pacific Mice Model Generation Market Attractiveness Index, by Technology, 2022–2031
Figure 40: Asia Pacific Mice Model Generation Market Value Share Analysis, by End-user, 2021 and 2031
Figure 41: Asia Pacific Mice Model Generation Market Attractiveness Analysis, by End-user, 2022–2031
Figure 42: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, 2017–2031
Figure 44: Latin America Mice Model Generation Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
Figure 43: Latin America Mice Model Generation Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 45: Latin America Mice Model Generation Market Value Share Analysis, by Technology, 2021 and 2031
Figure 46: Latin America Mice Model Generation Market Attractiveness Analysis, by Technology, 2022–2031
Figure 47: Latin America Mice Model Generation Market Value Share Analysis, by End-user, 2021 and 2031
Figure 48: Latin America Mice Model Generation Market Attractiveness Analysis, by End-user, 2022–2031
Figure 49: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, 2017–2031
Figure 51: Middle East & Africa Mice Model Generation Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
Figure 50: Middle East & Africa Mice Model Generation Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 52: Middle East & Africa Mice Model Generation Market Value Share Analysis, by Technology, 2021 and 2031
Figure 53: Middle East & Africa Mice Model Generation Market Attractiveness Analysis, by Technology, 2022–2031
Figure 54: Middle East & Africa Mice Model Generation Market Value Share Analysis, by End-user, 2021 and 2031
Figure 55: Middle East & Africa Mice Model Generation Market Attractiveness Analysis, by End-user, 2022–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Mice Model Generation Market
